These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
773 related articles for article (PubMed ID: 31980173)
1. Use of chimeric antigen receptor NK-92 cells to target mesothelin in ovarian cancer. Cao B; Liu M; Wang L; Liang B; Feng Y; Chen X; Shi Y; Zhang J; Ye X; Tian Y; Zhi C; Li J; Lian H; Wu Q; Zhang Z Biochem Biophys Res Commun; 2020 Mar; 524(1):96-102. PubMed ID: 31980173 [TBL] [Abstract][Full Text] [Related]
2. Development of mesothelin-specific CAR NK-92 cells for the treatment of gastric cancer. Cao B; Liu M; Huang J; Zhou J; Li J; Lian H; Huang W; Guo Y; Yang S; Lin L; Cai M; Zhi C; Wu J; Liang L; Hu Y; Hu H; He J; Liang B; Zhao Q; Zhu K Int J Biol Sci; 2021; 17(14):3850-3861. PubMed ID: 34671203 [No Abstract] [Full Text] [Related]
3. Disruption of adenosine 2A receptor improves the anti-tumor function of anti-mesothelin CAR T cells both in vitro and in vivo. Liu G; Zhang Q; Liu G; Li D; Zhang L; Gu Z; Tian H; Zhang Y; Tian X Exp Cell Res; 2021 Dec; 409(1):112886. PubMed ID: 34673000 [TBL] [Abstract][Full Text] [Related]
4. CAR memory-like NK cells targeting the membrane proximal domain of mesothelin demonstrate promising activity in ovarian cancer. Tarannum M; Dinh K; Vergara J; Birch G; Abdulhamid YZ; Kaplan IE; Ay O; Maia A; Beaver O; Sheffer M; Shapiro R; Ali AK; Dong H; Ham JD; Bobilev E; James S; Cameron AB; Nguyen QD; Ganapathy S; Chayawatto C; Koreth J; Paweletz CP; Gokhale PC; Barbie DA; Matulonis UA; Soiffer RJ; Ritz J; Porter RL; Chen J; Romee R Sci Adv; 2024 Jul; 10(28):eadn0881. PubMed ID: 38996027 [TBL] [Abstract][Full Text] [Related]
5. NK-92MI Cells Engineered with Anti-claudin-6 Chimeric Antigen Receptors in Immunotherapy for Ovarian Cancer. Li J; Hu H; Lian H; Yang S; Liu M; He J; Cao B; Chen D; Hu Y; Zhi C; Shen Y; Ye X; He B; Zhao M; Fan W; Xu L; Leidner R; Wu Q; Yang L; Zhang Z Int J Biol Sci; 2024; 20(5):1578-1601. PubMed ID: 38481806 [No Abstract] [Full Text] [Related]
6. Co-expression patterns of chimeric antigen receptor (CAR)-T cell target antigens in primary and recurrent ovarian cancer. Banville AC; Wouters MCA; Oberg AL; Goergen KM; Maurer MJ; Milne K; Ashkani J; Field E; Ghesquiere C; Jones SJM; Block MS; Nelson BH Gynecol Oncol; 2021 Feb; 160(2):520-529. PubMed ID: 33342620 [TBL] [Abstract][Full Text] [Related]
7. Anti-αFR CAR-engineered NK-92 Cells Display Potent Cytotoxicity Against αFR-positive Ovarian Cancer. Ao X; Yang Y; Li W; Tan Y; Guo W; Ao L; He X; Wu X; Xia J; Xu X; Guo J J Immunother; 2019 Oct; 42(8):284-296. PubMed ID: 31261167 [TBL] [Abstract][Full Text] [Related]
8. Dominant-negative transforming growth factor-β receptor-armoured mesothelin-targeted chimeric antigen receptor T cells slow tumour growth in a mouse model of ovarian cancer. Li K; Xu J; Wang J; Lu C; Dai Y; Dai Q; Zhang W; Xu C; Wu S; Kang Y Cancer Immunol Immunother; 2023 Apr; 72(4):917-928. PubMed ID: 36166071 [TBL] [Abstract][Full Text] [Related]
9. Development of Anti-Human Mesothelin-Targeted Chimeric Antigen Receptor Messenger RNA-Transfected Peripheral Blood Lymphocytes for Ovarian Cancer Therapy. Hung CF; Xu X; Li L; Ma Y; Jin Q; Viley A; Allen C; Natarajan P; Shivakumar R; Peshwa MV; Emens LA Hum Gene Ther; 2018 May; 29(5):614-625. PubMed ID: 29334771 [TBL] [Abstract][Full Text] [Related]
10. Chemokine Receptor CCR2b Enhanced Anti-tumor Function of Chimeric Antigen Receptor T Cells Targeting Mesothelin in a Non-small-cell Lung Carcinoma Model. Wang Y; Wang J; Yang X; Yang J; Lu P; Zhao L; Li B; Pan H; Jiang Z; Shen X; Liang Z; Liang Y; Zhu H Front Immunol; 2021; 12():628906. PubMed ID: 33777013 [TBL] [Abstract][Full Text] [Related]
11. Impact of fludarabine and treosulfan on ovarian tumor cells and mesothelin chimeric antigen receptor T cells. El-Serafi I; Micallef Nilsson I; Moter A; Duan Z; Mattsson J; Magalhaes I Cancer Immunol Immunother; 2024 Jul; 73(9):163. PubMed ID: 38954005 [TBL] [Abstract][Full Text] [Related]
12. Mesothelin-targeted CAR-NK Cells Derived From Induced Pluripotent Stem Cells Have a High Efficacy in Killing Triple-negative Breast Cancer Cells as Shown in Several Preclinical Models. Yang M; Guan T; Chen CF; He LF; Wu HM; Zhang RD; Li Y; Lin YC; Zeng H; Wu JD J Immunother; 2023 Oct; 46(8):285-294. PubMed ID: 37584622 [TBL] [Abstract][Full Text] [Related]
13. Mesothelin-targeted CAR-T therapy combined with irinotecan for the treatment of solid cancer. Zhu Y; Zuo D; Wang K; Lan S; He H; Chen L; Chen X; Feng M J Cancer Res Clin Oncol; 2023 Nov; 149(16):15027-15038. PubMed ID: 37612388 [TBL] [Abstract][Full Text] [Related]
14. [Killing effect of anti-MSLN-iCAR-NK cells derived from induced pluripotent stem cells on ovarian epithelial cancer cells]. Fan RJ; Zhang YF; Wang YY; Wang Y; Zheng W Zhonghua Fu Chan Ke Za Zhi; 2023 Dec; 58(12):922-929. PubMed ID: 38123198 [No Abstract] [Full Text] [Related]
15. Therapeutic effect of dual CAR-T targeting PDL1 and MUC16 antigens on ovarian cancer cells in mice. Li T; Wang J BMC Cancer; 2020 Jul; 20(1):678. PubMed ID: 32689954 [TBL] [Abstract][Full Text] [Related]
16. High Cytotoxic Efficiency of Lentivirally and Alpharetrovirally Engineered CD19-Specific Chimeric Antigen Receptor Natural Killer Cells Against Acute Lymphoblastic Leukemia. Müller S; Bexte T; Gebel V; Kalensee F; Stolzenberg E; Hartmann J; Koehl U; Schambach A; Wels WS; Modlich U; Ullrich E Front Immunol; 2019; 10():3123. PubMed ID: 32117200 [TBL] [Abstract][Full Text] [Related]
17. Modified CAR T cells targeting membrane-proximal epitope of mesothelin enhances the antitumor function against large solid tumor. Zhang Z; Jiang D; Yang H; He Z; Liu X; Qin W; Li L; Wang C; Li Y; Li H; Xu H; Jin H; Qian Q Cell Death Dis; 2019 Jun; 10(7):476. PubMed ID: 31209210 [TBL] [Abstract][Full Text] [Related]
18. Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer. Lv J; Zhao R; Wu D; Zheng D; Wu Z; Shi J; Wei X; Wu Q; Long Y; Lin S; Wang S; Wang Z; Li Y; Chen Y; He Q; Chen S; Yao H; Liu Z; Tang Z; Yao Y; Pei D; Liu P; Zhang X; Zhang Z; Cui S; Chen R; Li P J Hematol Oncol; 2019 Feb; 12(1):18. PubMed ID: 30777106 [TBL] [Abstract][Full Text] [Related]
19. Anti-mesothelin CAR-T immunotherapy in patients with ovarian cancer. Chen J; Hu J; Gu L; Ji F; Zhang F; Zhang M; Li J; Chen Z; Jiang L; Zhang Y; Shi R; Ma L; Jia S; Zhang Y; Zhang Q; Liang J; Yao S; Hu Z; Guo Z Cancer Immunol Immunother; 2023 Feb; 72(2):409-425. PubMed ID: 35925286 [TBL] [Abstract][Full Text] [Related]
20. Novel mesothelin-targeted chimeric antigen receptor-modified UNKT cells are highly effective in inhibiting tumor progression. Jiang W; Gu G; Zhang Y; Song Y; Shi M; Wang G; Li H; Tao T; Qin J; Li X; Jia H; Jiao F; Xu W; Huang X Pharmacol Res; 2023 Nov; 197():106942. PubMed ID: 37775021 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]